List of Korsuva drug patents
Korsuva is owned by Cara Therap.
Korsuva contains Difelikefalin Acetate.
Korsuva has a total of 12 drug patents out of which 0 drug patents have expired.
Korsuva was authorised for market use on 23 August, 2021.
Korsuva is available in solution;intravenous dosage forms.
Korsuva can be used as treatment of moderate-to-severe pruritus associated with chronic kidney disease (ckd-ap) in adults undergoing hemodialysis (hd).
Drug patent challenges can be filed against Korsuva from 2025-08-23.
The generics of Korsuva are possible to be released after 12 November, 2027.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US10793596 | CARA THERAP | Synthetic peptide amides |
Nov, 2027
(4 years from now) | |
| US10017536 | CARA THERAP | Synthetic peptide amides and dimers thereof |
Nov, 2027
(4 years from now) | |
| US8536131 | CARA THERAP | Synthetic peptide amides and dimers thereof |
Nov, 2027
(4 years from now) | |
| US7727963 | CARA THERAP | Synthetic peptide amides |
Nov, 2027
(4 years from now) | |
| US7713937 | CARA THERAP | Synthetic peptide amides and dimeric forms thereof |
Nov, 2027
(4 years from now) | |
| US7402564 | CARA THERAP | Synthetic peptide amides |
Nov, 2027
(4 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10138270 | CARA THERAP | Synthetic peptide amides |
Nov, 2027
(4 years from now) | |
| US9359399 | CARA THERAP | Synthetic peptide amides |
Nov, 2027
(4 years from now) | |
| US9334305 | CARA THERAP | Synthetic peptide amides and dimers thereof |
Nov, 2027
(4 years from now) | |
| US8486894 | CARA THERAP | Synthetic peptide amides and dimeric forms thereof |
Nov, 2027
(4 years from now) | |
| US8236766 | CARA THERAP | Uses of synthetic peptide amides |
Nov, 2027
(4 years from now) | |
| US8217007 | CARA THERAP | Synthetic peptide amides |
Nov, 2027
(4 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Aug 23, 2026 |
Drugs and Companies using DIFELIKEFALIN ACETATE ingredient
NCE-1 date: 2025-08-23
Market Authorisation Date: 23 August, 2021
Treatment: Treatment of moderate-to-severe pruritus associated with chronic kidney disease (ckd-ap) in adults undergoing hemodialysis (hd)
Dosage: SOLUTION;INTRAVENOUS
KORSUVA family patents
32
United States
3
Korea, Republic of
3
Japan
3
Canada
2
Malaysia
2
Russia
2
New Zealand
2
Mexico
2
China
2
South Africa
2
Israel
2
Australia
2
European Union
1
Portugal
1
Spain
1
Brazil
1
Hong Kong
1
Lithuania
1
Cyprus
1
Hungary
1
Slovenia
1
Poland
1
Denmark
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic